ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2019

The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.

Jong Woo Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.